FDA warned semaspace.com for selling unapproved, misbranded injectable semaglutide drugs online without prescriptions.
What happened
FDA reviewed www.semaspace.com and found it offering “Semaglutide 2mg” and “Semaglutide 5mg” injectable products for weight loss and related uses. FDA said there are no approved applications for these products and that the site offered prescription drugs without requiring a prescription. FDA also said the labeling lacked adequate directions for use.
What FDA found
The company sold semaglutide injection products that FDA treats as unapproved new drugs, meaning they lack the FDA approval required for new drugs.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The products’ labeling did not have adequate directions for safe use by a layperson, so FDA calls them misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5; 21 CFR 201.115(a)The website offered prescription semaglutide drugs without requiring a prescription from a licensed healthcare practitioner.
FD&C Act section 503(b)(1) [21 U.S.C. § 353(b)(1)]; section 301(k) [21 U.S.C. § 331(k)]Offering these drugs for sale to U.S. consumers caused misbranded drugs to enter interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks semaspace.com to stop offering any unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days describing corrective steps and how it will prevent recurrence.
Who should pay attention
- consumers buying semaglutide online
- online pharmacies and telehealth sites selling GLP-1 drugs
- companies sourcing or distributing semaglutide injections
This is a summary. Read the original letter on fda.gov.